Selected article for: "significant challenge and vaccine development"
Author: Roper, Rachel L; Rehm, Kristina E
Title: SARS vaccines: where are we?
  • Cord-id: y4eyse0y
  • Document date: 2014_1_9
    • ID: y4eyse0y
    Snippet: In this review, the current state of vaccine development against human severe acute respiratory syndrome (SARS) coronavirus, focusing on recently published data is assessed. We discuss which strategies have been assessed immunologically and which have been evaluated in SARS coronavirus challenge models. We discuss inactivated vaccines, virally and bacterially vectored vaccines, recombinant protein and DNA vaccines, as well as the use of attenuated vaccines. Data regarding the correlates of prote
    Document: In this review, the current state of vaccine development against human severe acute respiratory syndrome (SARS) coronavirus, focusing on recently published data is assessed. We discuss which strategies have been assessed immunologically and which have been evaluated in SARS coronavirus challenge models. We discuss inactivated vaccines, virally and bacterially vectored vaccines, recombinant protein and DNA vaccines, as well as the use of attenuated vaccines. Data regarding the correlates of protection, animal models and the available evidence regarding potential vaccine enhancement of SARS disease are discussed. While there is much evidence that various vaccine strategies against SARS are safe and immunogenic, vaccinated animals still display significant disease upon challenge. Current data suggest that intranasal vaccination may be crucial and that new or combination strategies may be required for good protective efficacy against SARS in humans.

    Search related documents:
    Co phrase search for related documents
    • absence presence and ad vaccine: 1
    • absence presence and adenovirus ad: 1
    • absence presence and administration route: 1
    • absence presence and live vaccine: 1
    • absence presence and live virus: 1, 2
    • absence presence and liver damage: 1, 2
    • absence presence and low respiratory: 1
    • absence presence and lung damage: 1, 2
    • absence presence and lung fever: 1
    • absence presence and lung pathology: 1
    • absence presence and lung replication: 1
    • absence presence and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and lung viral load: 1
    • accelerated vaccine initiative and acute respiratory syndrome: 1, 2